INTRODUCTION: HIV treatment guidelines recommend initiating antiretroviral therapy (ART) regardless of CD4 cell (CD4) count, barring contraindications or barriers to treatment. An estimated 6% of persons receiving HIV care in 2013 were not prescribed ART. We examined reasons for this gap in the care continuum. METHODS: During 2013-2014, we surveyed a probability sample of HIV care providers, of whom 1234 returned surveys (64.0% adjusted response rate). We estimated percentages of providers who followed guidelines and their characteristics, and who deferred ART prescribing for any reason. RESULTS: Barring contraindications, 71.2% of providers initiated ART regardless of CD4 count. Providers less likely to initiate had caseloads ≤20 vs. >200 patients [adjusted prevalence ratios (aPR) 0.69, 95% confidence interval (CI): 0.47 to 1.02, P = 0.03], practiced at non-Ryan White HIV/AIDS Program-funded facilities (aPR 0.85, 95% CI: 0.74 to 0.98, P = 0.02), or reported pharmaceutical assistance programs provided insufficient medication to meet patients' needs (aPR 0.79, 95% CI: 0.65 to 0.98, P = 0.02). In all, 17.0% never deferred prescribing ART, 69.6% deferred for 1%-10% of patients, and 13.3% deferred for >10%. Among providers who had deferred ART, 59.4% cited patient refusal as a reason in >50% of cases, 31.1% reported adherence concerns because of mental health disorders or substance abuse, and 21.4% reported adherence concerns because of social problems, eg, homelessness, as factors in >50% of cases when deferring ART. CONCLUSIONS: An estimated 29% of HIV care providers had not adopted recommendations to initiate ART regardless of CD4 count, barring contraindications, or barriers to treatment. Low-volume providers and those at non-Ryan White HIV/AIDS Program-funded facilities were less likely to follow this guideline. Among all providers, leading reasons for deferring ART included patient refusal and adherence concerns.
INTRODUCTION: HIV treatment guidelines recommend initiating antiretroviral therapy (ART) regardless of CD4 cell (CD4) count, barring contraindications or barriers to treatment. An estimated 6% of persons receiving HIV care in 2013 were not prescribed ART. We examined reasons for this gap in the care continuum. METHODS: During 2013-2014, we surveyed a probability sample of HIV care providers, of whom 1234 returned surveys (64.0% adjusted response rate). We estimated percentages of providers who followed guidelines and their characteristics, and who deferred ART prescribing for any reason. RESULTS: Barring contraindications, 71.2% of providers initiated ART regardless of CD4 count. Providers less likely to initiate had caseloads ≤20 vs. >200 patients [adjusted prevalence ratios (aPR) 0.69, 95% confidence interval (CI): 0.47 to 1.02, P = 0.03], practiced at non-Ryan White HIV/AIDS Program-funded facilities (aPR 0.85, 95% CI: 0.74 to 0.98, P = 0.02), or reported pharmaceutical assistance programs provided insufficient medication to meet patients' needs (aPR 0.79, 95% CI: 0.65 to 0.98, P = 0.02). In all, 17.0% never deferred prescribing ART, 69.6% deferred for 1%-10% of patients, and 13.3% deferred for >10%. Among providers who had deferred ART, 59.4% cited patient refusal as a reason in >50% of cases, 31.1% reported adherence concerns because of mental health disorders or substance abuse, and 21.4% reported adherence concerns because of social problems, eg, homelessness, as factors in >50% of cases when deferring ART. CONCLUSIONS: An estimated 29% of HIV care providers had not adopted recommendations to initiate ART regardless of CD4 count, barring contraindications, or barriers to treatment. Low-volume providers and those at non-Ryan White HIV/AIDS Program-funded facilities were less likely to follow this guideline. Among all providers, leading reasons for deferring ART included patient refusal and adherence concerns.
Authors: Parya Saberi; Torsten B Neilands; Eric Vittinghoff; Mallory O Johnson; Margaret Chesney; Susan E Cohn Journal: AIDS Patient Care STDS Date: 2015-01-23 Impact factor: 5.078
Authors: D R Bangsberg; F M Hecht; E D Charlebois; A R Zolopa; M Holodniy; L Sheiner; J D Bamberger; M A Chesney; A Moss Journal: AIDS Date: 2000-03-10 Impact factor: 4.177
Authors: Maeve O'Neill; Gregory D Karelas; Daniel J Feller; Emily Knudsen-Strong; Dawn Lajeunesse; Dennis Tsui; Peter Gordon; Bruce D Agins Journal: Clin Infect Dis Date: 2015-09-30 Impact factor: 9.079
Authors: D R Bangsberg; F M Hecht; H Clague; E D Charlebois; D Ciccarone; M Chesney; A Moss Journal: J Acquir Immune Defic Syndr Date: 2001-04-15 Impact factor: 3.731
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Tuan Le; Edwina J Wright; Davey M Smith; Weijing He; Gabriel Catano; Jason F Okulicz; Jason A Young; Robert A Clark; Douglas D Richman; Susan J Little; Sunil K Ahuja Journal: N Engl J Med Date: 2013-01-17 Impact factor: 91.245
Authors: Linda Beer; Eduardo E Valverde; Jerris L Raiford; John Weiser; Becky L White; Jacek Skarbinski Journal: J Int Assoc Provid AIDS Care Date: 2014-11-12
Authors: Heather Bradley; H Irene Hall; Richard J Wolitski; Michelle M Van Handel; Amy E Stone; Michael LaFlam; Jacek Skarbinski; Darrel H Higa; Joseph Prejean; Emma L Frazier; Roshni Patel; Ping Huang; Qian An; Ruiguang Song; Tian Tang; Linda A Valleroy Journal: MMWR Morb Mortal Wkly Rep Date: 2014-11-28 Impact factor: 17.586
Authors: John Weiser; Guangnan Chen; Linda Beer; Daria Boccher-Lattimore; Wendy Armstrong; Ann Kurth; R Luke Shouse Journal: Health Serv Res Date: 2019-07-01 Impact factor: 3.402
Authors: Serena Rajabiun; Janell Tryon; Matt Feaster; Amy Pan; Lisa McKeithan; Karen Fortu; Howard J Cabral; Deborah Borne; Frederick L Altice Journal: Am J Public Health Date: 2018-12 Impact factor: 9.308
Authors: Mohammad Zubair Harooni; Abdul Alim Atarud; Ehsanullah Ehsan; Ajmal Alokozai; Willi McFarland; Ali Mirzazadeh Journal: Int J STD AIDS Date: 2021-12-15 Impact factor: 1.359
Authors: José F Figueroa; Ingrid T Katz; Emily P Hyle; Kathryn E Horneffer; Kavya Nambiar; Jessica Phelan; E John Orav; Ashish K Jha Journal: Health Aff (Millwood) Date: 2022-04 Impact factor: 9.048
Authors: John Weiser; Linda Beer; John T Brooks; Kathleen Irwin; Brady T West; Christopher C Duke; Garrett W Gremel; Jacek Skarbinski Journal: J Int Assoc Provid AIDS Care Date: 2017-09-13
Authors: Rose S Bono; Bassam Dahman; Lindsay M Sabik; Lauren E Yerkes; Yangyang Deng; Faye Z Belgrave; Daniel E Nixon; Anne G Rhodes; April D Kimmel Journal: Clin Infect Dis Date: 2021-05-04 Impact factor: 20.999
Authors: Joseph Cherabie; Patrick Mazi; Adriana M Rauseo; Chapelle Ayres; Lindsey Larson; Sasinuch Rutjanawech; Jane O'Halloran; Rachel Presti; William G Powderly; Andrej Spec Journal: J Fungi (Basel) Date: 2021-05-08